Skip to main content

Cancer: Drugs

Volume 507: debated on Tuesday 16 March 2010

To ask the Secretary of State for Health with reference to the answer of 10 November 2009, Official Report, column 242W, on cancer: drugs, (1) what period elapsed from the licensing of each drug referred to in the answer to the (a) draft and (b) final National Institute for Health and Clinical Excellence guidance being available; (322366)

(2) what cancer drugs have been appraised by the National Institute for Health and Clinical Excellence (NICE) since the answer; whether each was (a) recommended and (b) not recommended for NHS use; how long the appraisal of each took; whether the pharmaceutical company supplying each such drug offered to make it available through a patient access scheme; and how long it has taken from the licensing of each drug to draft and final NICE guidance being made available.

The information requested is shown in the table.

Topic

Single Technology Appraisal (STA) or Multiple Technology Appraisal (MTA)

Date of market authorisation for relevant indication

Start of NICE appraisal1

Date of draft NICE guidance

Date of final NICE guidance

Recommendation

Patient Access Scheme considered by NICE

Yondelis (trabectedin) for soft tissue sarcoma

STA

September 2007

September 2008

June 2009

February 2010

Partial recommendation

Yes

Hycamtin (topotecan) for small cell lung cancer

MTA

From January 2006

August 2008

July 2009

November 2009

Partial recommendation

No

Hycamtin (topotecan) for Cervical Cancer (recurrent)

STA

December 2006

December 2008

June 2009

October 2009

Partial recommendation

No

Sutent (sunitinib) for Gastrointestinal stromal tumours

STA

July 2006

August 2008

March 2009

September 2009

Partial recommendation

Yes

Alimta (pemetrexed) for the first-line treatment of non-small-cell lung cancer

STA

April 2008

October 2008

April 2009

September 2009

Partial recommendation

No

Erbitux (cetuximab) for Colorectal Cancer (first line)

STA

July 2008

January 2008

September 2008

August 2009

Partial recommendation

Yes

Avastin (bevacizumab) (first-line), Nexavar (sorafenib) (first-line and second-line), Sutent (sunitinib) (second-line) and Torisel (temsirolimus) (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

MTA

Nexavar—June 2006

September 20072

August 2008

August 2009

Not recommended

Nexavar—yes

Avastin—January 2008

Avastin— yes

Sutent—July 2006

Sutent—yes

Torisel—November 2007

Torisel—no

Mabthera (rituximab) for first-line treatment of chronic lymphocytic leukaemia

STA

February 2009

September 2008

March 2009

July 2009

Partial recommendation

No

Erbitux (cetuximab) for Head and Neck Cancer (squamous cell carcinoma)

STA

January 2009

September 2008

January 2009

June 2009

Not recommended

No

Revlimid (lenalidomide) for Multiple Myeloma

STA

June 2007

April 2008

October 2008

June 2009

Partial recommendation

Yes

Sutent (sunitinib) for the first-line treatment of advanced and/or metastatic renal cell carcinoma

MTA

July 2006

September 20072

August 2008

March 2009

Partial recommendation

Yes

Tarceva (erlotinib) for the treatment of non-small-cell lung cancer

STA

September 2005

March 2006

November 2006

November 2008

Partial recommendation

Yes

1 The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.

2 This is the date on which the MTA began for Avastin (bevacizumab) (first-line), Nexavar (sorafenib) (first-line and second-line), Sutent (sunitinib) (first and second-line) and Torisel (temsirolimus) (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. The MTA was subsequently split and Sutent (sunitinib) for the first-line treatment of renal cell carcinoma was considered in a separate STA.